Home › Activist investors › Iroquois Capital
Campaign activist. Positions and campaigns from Iroquois Capital’s SEC filings. Updated November 20, 2026.
No active campaign by this definition (see How to read this).
No current position by this definition.
Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.
| Company | Outcome or last status | Date | First filing | Highest stage | Filings | Meeting / votes |
|---|---|---|---|---|---|---|
| PharmaCyte Biotech, Inc.Board seats | Stake reported below 5% | Jun 16, 2023 | Jun 23, 2022 | Proxy contest filed (preliminary proxy) | latest (7) | — |
| Real Goods Solar, Inc. | Settled (agreement with the company) | Jan 3, 2018 | Jan 3, 2018 | — | latest (2) | — |
| Company | Last stake | Source | Outcome | Date |
|---|---|---|---|---|
| PharmaCyte Biotech, Inc. | 5.0% | Schedule 13D/A, filed Jun 16, 2023 | Reported below 5% in a 13D/A | Jun 16, 2023 |
Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.
No proxy contest has gone to a vote since July 1, 2023.
How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.
| Company | Outcome | Detail | Date | First filing |
|---|---|---|---|---|
| PharmaCyte Biotech, Inc. | Settlement | agreement with the company | Aug 16, 2022 | Jun 23, 2022 |
| Real Goods Solar, Inc. | Settlement | agreement with the company | Jun 7, 2018 | Jan 3, 2018 |
The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 0 of 1 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).
Terms of the cooperation agreements, read by rules from the company’s Form 8-K (or the investor’s 13D where it describes the agreement). Each term is quoted from the filing; terms a rule did not find are not listed, so a missing term is not evidence that the agreement lacks it.
“Pursuant to the Agreement, at the 2017 annual meeting of shareholders, Iroquois Capital agrees to appear in person or by proxy and vote all shares of the Company’s Class A common stock beneficially owned by Iroquois Capital and its “affiliates” and “associates” (as such terms are defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934, as amended) in favor of (i) the election of the Company’s director nominees, (ii) the approval of an amendment to the Comp…” 8-K, Jan 3, 2018